Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report published on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently issued reports on the company. HC Wainwright reaffirmed a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a report on Friday, November 8th. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Mizuho dropped their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. Finally, Barclays decreased their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. Nine equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Revance Therapeutics presently has a consensus rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Stock Performance

Shares of Revance Therapeutics stock opened at $3.28 on Monday. The company has a 50-day simple moving average of $3.51 and a two-hundred day simple moving average of $4.54. The stock has a market capitalization of $342.40 million, a PE ratio of -1.70 and a beta of 0.86. Revance Therapeutics has a 52-week low of $2.30 and a 52-week high of $7.56.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The company had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. As a group, equities research analysts forecast that Revance Therapeutics will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Revance Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Alpine Associates Management Inc. bought a new position in Revance Therapeutics in the third quarter worth approximately $21,605,000. LMR Partners LLP purchased a new stake in shares of Revance Therapeutics in the 3rd quarter worth $11,648,000. Stonepine Capital Management LLC raised its holdings in Revance Therapeutics by 41.7% in the 2nd quarter. Stonepine Capital Management LLC now owns 2,800,000 shares of the biopharmaceutical company’s stock worth $7,196,000 after purchasing an additional 823,658 shares during the period. Oddo BHF Asset Management Sas purchased a new position in Revance Therapeutics during the third quarter valued at $3,763,000. Finally, Federated Hermes Inc. grew its holdings in Revance Therapeutics by 43.0% during the second quarter. Federated Hermes Inc. now owns 2,237,505 shares of the biopharmaceutical company’s stock valued at $5,750,000 after purchasing an additional 672,803 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.